FILTER

FILTERED INTERVIEW RESULTS

Mining
MACIG

Liam Morrissey

CEO, MS RISK
"The real danger is that some companies may still want to trade off the old business model of six years ago."
Mining
MACIG

Sébastien de Montessus

PRESIDENT & CEO, ENDEAVOUR MINING
"Last year, we announced our goal to discover between 15 and 20 million oz Au by 2026. We are making good progress towards this goal with over 250,000 m drilled already this year."
Mining
MACIG

Ralph Heath & Ernest Krakani

MANAGING DIRECTOR: EARTH AND ENVIRONMENT, WSP IN AFRICA & COUNTRY LEAD FOR GOLDER│WSP IN GHANA / WEST AFRICA
The Golder team grew from 7,000 to over 61,000 people around the world.
Mining
MACIG

Cedric Fernandez

MANAGING DIRECTOR AFRICA POWER SERVICES
"There is no miner or junior that is not considering hybridizing existing or new power stations by adding more renewables into the mix."
Mining
Ghana
MACIG

Kwame Amponsah

GENERAL MANAGER, RAMOTH SERVICES
MACIG 2022
Ramoth Services supports mines with engineering and construction in Ghana.
Mining
Cote d’Ivoire
MACIG

Marc-Antoine Audet

CEO, SAMA RESOURCES
MACIG 2022
Sama Resources is exploring for nickel, copper and graphite in West Africa
Mining
Ghana
MACIG

NanaAma Botchway

MANAGING PARTNER, N. DOWUONA & COMPANY
MACIG 2022
N. Dowuona & Company is a predominantly female-owned and led law firm in Ghana and describes regulatory conditions for mining.
Mining
Niger
MACIG

Stephen G. Roman

PRESIDENT AND CEO, GLOBAL ATOMIC
MACIG 2022
Global Atomic explains progress at its Dasa uranium project in Niger.
Mining
Ghana
MACIG

Seth Asante

MANAGING PARTNER, BENTSI-ENCHILL, LETSA & ANKOMAH (BELA)
MACIG 2022
Ghanian law firm BELA explains recent changes to the country’s mining regulations.
Mining
Cote d’Ivoire
MACIG

Hugh Stuart

CEO, MONTAGE GOLD
MACIG 2022
Montage Gold outlines the potential of its Koné deposit in Ivory Coast.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL